The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients

The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients

Background: The standard recommendation for neoadjuvant therapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer patients is trastuzumab in combination with chemotherapy, but there is no current standard recommendation for appropriate chemotherapy regimens. This meta-analys...

Full description

Bibliographic Details
Main Authors:	Yuqin Ding, Kaijing Ding, Xiangming He, Wenju Mo, Chenlu Liang, Lijie Gong, Yuting Huang, Xiaowen Ding
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-09-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	https://doi.org/10.1177/11795549231195293

Similar Items

LncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p/CREB1 axis
by: Yuqin Ding, et al.
Published: (2023-11-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

P123 Optimal Regimen of Neoadjuvant Systemic Therapy for HER2 Positive Early Breast Cancer
by: C. Lo, et al.
Published: (2023-03-01)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
by: Binwei Lin MM, et al.
Published: (2023-11-01)

Effects of Different Neoadjuvant Chemotherapy Regimens on Immune Indicators and Tumor Microenvironment in HER-2-positive Breast Cancer Patients
by: PEI Bei, CHENG Lin, XU Lingyun
Published: (2023-09-01)

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
by: Jiujun Zhu, et al.
Published: (2022-09-01)

Henry II of Trastámara (1366–1367, 1369–1379)
by: María Ángeles Jordano Barbudo
Published: (2022-01-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
by: Cui Jiang, et al.
Published: (2019-09-01)

Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
by: Heyan Chen, et al.
Published: (2023-02-01)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
by: Azzurra Irelli, et al.
Published: (2022-06-01)

1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer
by: Ilona Hagelstein, et al.
Published: (2023-11-01)

MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS
by: P. V. Kazantseva, et al.
Published: (2016-07-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
by: Gavin P. Dowling, et al.
Published: (2023-01-01)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
by: Junyoung Shin, et al.
Published: (2023-02-01)

The application of grouting reinforcement to the broken surrounding rock of 1366 stoping roadway
by: Zhang Lixin, et al.
Published: (2023-08-01)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
by: Ariadna Tibau, et al.
Published: (2014-10-01)

Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
by: LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao
Published: (2022-05-01)

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen
by: Zhaoying Dong, et al.
Published: (2022-01-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
by: M. C. Liefaard, et al.
Published: (2024-04-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Anthracyclines
by: Alison Cheong, et al.
Published: (2018-12-01)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
by: Kaho Tateishi, et al.
Published: (2023-11-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
by: G. Griguolo, et al.
Published: (2021-03-01)

Storia giudiziaria della rivolta di San Tito a Creta (1363-1366)
by: Matteo Magnani
Published: (2013-04-01)

Early cellular events and potential regulators of cellulase induction in Penicillium janthinellum NCIM 1366
by: Meera Christopher, et al.
Published: (2023-03-01)

JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
by: Jin Mo Ku, et al.
Published: (2023-06-01)

The dual role of ferroptosis in anthracycline-based chemotherapy includes reducing resistance and increasing toxicity
by: Jiazheng Zhao, et al.
Published: (2023-06-01)

Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: María del Pilar Chantada-Vázquez, et al.
Published: (2022-02-01)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
by: Natalia Krawczyk, et al.
Published: (2022-06-01)

Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
by: Abdullah Evren YETİŞİR, et al.
Published: (2021-08-01)

<i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
by: María Gaibar, et al.
Published: (2022-01-01)

Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Agampodi Danushi M. Gunasekara, et al.
Published: (2022-01-01)

Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy
by: A A Avalyan, et al.
Published: (2018-12-01)

Per il Codice Diplomatico Poliano: una sentenza memorabile (Venezia, 13 luglio 1366)
by: Vittorio Formentin, et al.
Published: (2024-04-01)

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
by: Alberto Alvarez-Larrán, et al.
Published: (2023-08-01)